ProKidney (NASDAQ:PROK – Get Free Report) and TG Therapeutics (NASDAQ:TGTX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.
Volatility & Risk
ProKidney has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for ProKidney and TG Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 1 | 0 | 2 | 1 | 2.75 |
| TG Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
ProKidney presently has a consensus target price of $10.00, suggesting a potential upside of 856.94%. TG Therapeutics has a consensus target price of $63.00, suggesting a potential downside of 2.34%. Given ProKidney’s higher probable upside, research analysts clearly believe ProKidney is more favorable than TG Therapeutics.
Profitability
This table compares ProKidney and TG Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -13,326.71% | N/A | -35.31% |
| TG Therapeutics | 11.81% | 18.82% | 7.78% |
Institutional & Insider Ownership
51.6% of ProKidney shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 39.8% of ProKidney shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares ProKidney and TG Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $890,000.00 | 354.97 | -$68.99 million | ($0.55) | -1.90 |
| TG Therapeutics | $897.76 million | 10.86 | $447.18 million | $0.66 | 97.74 |
TG Therapeutics has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
TG Therapeutics beats ProKidney on 10 of the 14 factors compared between the two stocks.
About ProKidney
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
